Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe
December 21 2021 - 8:00AM
Business Wire
- Real-time glucose data and alerts from the world’s first and
only long-term CGM system can now be remotely monitored by friends
and family of Eversense users on Android and iOS operating
system
Senseonics Holdings, Inc. (NYSE American: SENS) a medical
technology company focused on the development and manufacturing of
long-term, implantable continuous glucose monitoring (CGM) systems
for people with diabetes, today announced it received CE mark of
the Eversense® NOW Remote Monitoring App for the Android Operating
System. The Eversense NOW iOS platform has previously been approved
and is currently available in Europe.
“We’re pleased to offer yet another tool for our Eversense users
in Europe, now enabling access to this important feature for all
our customers,” said Tim Goodnow, PhD, President and CEO of
Senseonics. “With the Eversense NOW app, Eversense users can enjoy
the added peace of mind that comes with knowing friends and family
can remotely view real-time glucose data, see trend graphs, and
receive real-time glucose alerts from anywhere.”
The Eversense NOW Remote Monitoring app for the Android
operating system is expected to be available starting in the first
quarter of 2022 on the Google Play™ Store.
About Eversense
The Eversense® XL Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age
18 and older with diabetes for up to 180 days. The system is
intended to complement, not replace, fingerstick blood glucose (BG)
measurements for diabetes treatment decisions. The sensor insertion
and removal procedures are performed by a health care provider. The
Eversense XL CGM System is a prescription device; patients should
talk to their health care provider to learn more. For important
safety information, see
https://global.eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company
focused on the development and manufacturing of glucose monitoring
products designed to transform lives in the global diabetes
community with differentiated, long-term implantable glucose
management technology. Senseonics' CGM systems, Eversense® and
Eversense® XL, include a small sensor inserted completely under the
skin that communicates with a smart transmitter worn over the
sensor. The glucose data are automatically sent every 5 minutes to
a mobile app on the user's smartphone.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Senseonics, including the availability and
market acceptance of the Eversense NOW Remote Monitoring app, and
other statements containing the words “believe,” “expect,”
“intend,” “may,” “projects,” “will,” “planned,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: uncertainties in the development and regulatory
approval processes and timing for the 180-day Eversense product,
uncertainties inherent in the commercial launch and commercial
expansion of the Eversense product, uncertainties inherent in the
transition of commercialization responsibilities to Ascensia
Diabetes Care, uncertainties in insurer, regulatory and
administrative processes and decisions, uncertainties in the
duration and severity of the COVID-19 pandemic, and such other
factors as are set forth in the risk factors detailed in
Senseonics’ Annual Report on Form 10-K for the year ended December
31, 2020, Senseonics’ Quarterly Report on Form 10-Q for the quarter
ended September 30, 2021 and Senseonics’ other filings with the SEC
under the heading “Risk Factors.” In addition, the forward-looking
statements included in this press release represent Senseonics’
views as of the date hereof. Senseonics anticipates that subsequent
events and developments will cause Senseonics’ views to change.
However, while Senseonics may elect to update these forward-looking
statements at some point in the future, Senseonics specifically
disclaims any obligation to do so except as required by law. These
forward-looking statements should not be relied upon as
representing Senseonics’ views as of any date subsequent to the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211221005266/en/
Senseonics Investor Contact Lynn Lewis or Philip Taylor
Investor Relations 415-937-5406 investors@senseonics.com
Senseonics (AMEX:SENS)
Historical Stock Chart
From May 2024 to Jun 2024
Senseonics (AMEX:SENS)
Historical Stock Chart
From Jun 2023 to Jun 2024